Table 1 summarizes the clinical, demographic, and pathological characteristics of the patients. Based on the 2021 WHO classification of CNS tumors, the tumors were classified into IDH-mutation and 1p/19q intact glioma (WHO grade 2 astrocytoma, n=3; WHO grade 3 astrocytoma, n=3; WHO grade 4 astrocytoma, n=3), IDH-mutation and 1p/19q codeletion glioma (WHO grade 2 oligodendroglioma, n=7; WHO grade 3 oligodendroglioma, n=8), and IDH-wild-type glioma (WHO grade 4 glioblastoma, n=24). Patients with IDH wild-type glioma were found to be older than those with IDH-mutation glioma. Here, IDH1 is linked to central nervous system neoplasm.